154 related articles for article (PubMed ID: 33672039)
1. Effect of C-terminus Conjugation via Different Conjugation Chemistries on In Vivo Activity of Albumin-Conjugated Recombinant GLP-1.
Park J; Bak M; Min K; Kim HW; Cho JH; Tae G; Kwon I
Pharmaceutics; 2021 Feb; 13(2):. PubMed ID: 33672039
[TBL] [Abstract][Full Text] [Related]
2. Recombinant Peptide Production Platform Coupled with Site-Specific Albumin Conjugation Enables a Convenient Production of Long-Acting Therapeutic Peptide.
Bak M; Park J; Min K; Cho J; Seong J; Hahn YS; Tae G; Kwon I
Pharmaceutics; 2020 Apr; 12(4):. PubMed ID: 32316169
[TBL] [Abstract][Full Text] [Related]
3. Multivalent Albumin-Neonatal Fc Receptor Interactions Mediate a Prominent Extension of the Serum Half-Life of a Therapeutic Protein.
Yang B; Kwon I
Mol Pharm; 2021 Jun; 18(6):2397-2405. PubMed ID: 33983743
[TBL] [Abstract][Full Text] [Related]
4. Glucagon-like Peptide 1 Conjugated to Recombinant Human Serum Albumin Variants with Modified Neonatal Fc Receptor Binding Properties. Impact on Molecular Structure and Half-Life.
Bukrinski JT; Sønderby P; Antunes F; Andersen B; Schmidt EGW; Peters GHJ; Harris P
Biochemistry; 2017 Sep; 56(36):4860-4870. PubMed ID: 28799326
[TBL] [Abstract][Full Text] [Related]
5. Site-specific albumination of a therapeutic protein with multi-subunit to prolong activity in vivo.
Lim SI; Hahn YS; Kwon I
J Control Release; 2015 Jun; 207():93-100. PubMed ID: 25862515
[TBL] [Abstract][Full Text] [Related]
6. Enhanced therapeutic potential of antibody fragment via IEDDA-mediated site-specific albumin conjugation.
Go EB; Lee JH; Cho JH; Kwon NH; Choi JI; Kwon I
J Biol Eng; 2024 Apr; 18(1):23. PubMed ID: 38576037
[TBL] [Abstract][Full Text] [Related]
7. Microbially produced glucagon-like peptide 1 improves glucose tolerance in mice.
Arora T; Wegmann U; Bobhate A; Lee YS; Greiner TU; Drucker DJ; Narbad A; Bäckhed F
Mol Metab; 2016 Aug; 5(8):725-730. PubMed ID: 27656410
[TBL] [Abstract][Full Text] [Related]
8. Genetically Encoding a Lipidated Amino Acid for Extension of Protein Half-Life in vivo.
Fu C; Chen Q; Zheng F; Yang L; Li H; Zhao Q; Wang X; Wang L; Wang Q
Angew Chem Int Ed Engl; 2019 Jan; 58(5):1392-1396. PubMed ID: 30474173
[TBL] [Abstract][Full Text] [Related]
9. Comparative studies of the serum half-life extension of a protein via site-specific conjugation to a species-matched or -mismatched albumin.
Yang B; Kim JC; Seong J; Tae G; Kwon I
Biomater Sci; 2018 Jul; 6(8):2092-2100. PubMed ID: 29881837
[TBL] [Abstract][Full Text] [Related]
10. Generation of therapeutic protein variants with the human serum albumin binding capacity via site-specific fatty acid conjugation.
Cho J; Lim SI; Yang BS; Hahn YS; Kwon I
Sci Rep; 2017 Dec; 7(1):18041. PubMed ID: 29269881
[TBL] [Abstract][Full Text] [Related]
11. Novel mono-PEGylated dimeric GLP-1 conjugate with enhanced receptor activation and prolonged anti-diabetes efficacies.
Li P; Zhang J; Jia Y; Zhang Y
Life Sci; 2020 Aug; 254():117752. PubMed ID: 32387412
[TBL] [Abstract][Full Text] [Related]
12. Expression, purification, and characterization of recombinant human serum albumin fusion protein with two human glucagon-like peptide-1 mutants in Pichia pastoris.
Dou WF; Lei JY; Zhang LF; Xu ZH; Chen Y; Jin J
Protein Expr Purif; 2008 Sep; 61(1):45-9. PubMed ID: 18556214
[TBL] [Abstract][Full Text] [Related]
13. Effects of GW002, a novel recombinant human glucagon-like peptide-1 (GLP-1) analog fusion protein, on CHO recombinant cells and BKS-db mice.
Ji WW; Yu DA; Fan M; You M; Lu Y; Li EB; Xie N; Yan SS
Acta Diabetol; 2017 Jul; 54(7):685-693. PubMed ID: 28424924
[TBL] [Abstract][Full Text] [Related]
14. Development and characterization of a glucagon-like peptide 1-albumin conjugate: the ability to activate the glucagon-like peptide 1 receptor in vivo.
Kim JG; Baggio LL; Bridon DP; Castaigne JP; Robitaille MF; Jetté L; Benquet C; Drucker DJ
Diabetes; 2003 Mar; 52(3):751-9. PubMed ID: 12606517
[TBL] [Abstract][Full Text] [Related]
15. Addition of a cysteine to glucagon-like peptide-1 (GLP-1) conjugates GLP-1 to albumin in serum and prolongs GLP-1 action in vivo.
Wu YL; Huang J; Xu J; Liu J; Feng Z; Wang Y; Lai Y; Wu ZR
Regul Pept; 2010 Sep; 164(2-3):83-9. PubMed ID: 20570598
[TBL] [Abstract][Full Text] [Related]
16. A GLP-1 receptor agonist conjugated to an albumin-binding domain for extended half-life.
Lindgren J; Refai E; Zaitsev SV; Abrahmsén L; Berggren PO; Karlström AE
Biopolymers; 2014 May; 102(3):252-9. PubMed ID: 24549714
[TBL] [Abstract][Full Text] [Related]
17. Variant fatty acid-like molecules Conjugation, novel approaches for extending the stability of therapeutic peptides.
Li Y; Wang Y; Wei Q; Zheng X; Tang L; Kong D; Gong M
Sci Rep; 2015 Dec; 5():18039. PubMed ID: 26658631
[TBL] [Abstract][Full Text] [Related]
18. Site-Specific Albumination as an Alternative to PEGylation for the Enhanced Serum Half-Life in Vivo.
Yang B; Lim SI; Kim JC; Tae G; Kwon I
Biomacromolecules; 2016 May; 17(5):1811-7. PubMed ID: 27050863
[TBL] [Abstract][Full Text] [Related]
19. A recombinant human glucagon-like peptide (GLP)-1-albumin protein (albugon) mimics peptidergic activation of GLP-1 receptor-dependent pathways coupled with satiety, gastrointestinal motility, and glucose homeostasis.
Baggio LL; Huang Q; Brown TJ; Drucker DJ
Diabetes; 2004 Sep; 53(9):2492-500. PubMed ID: 15331566
[TBL] [Abstract][Full Text] [Related]
20. Glucagon-like peptide-1 plasmid construction and delivery for the treatment of type 2 diabetes.
Choi S; Oh S; Lee M; Kim SW
Mol Ther; 2005 Nov; 12(5):885-91. PubMed ID: 16039908
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
